Main Story
-
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities
Proposed acquisition of an Israeli company with approximately 20 years of operating experience is expected to strengthen BiomX’s Detection-Analysis-Response strategy through security systems, fire detection, access control, intrusion detection, building-control, electrical infrastructure and secure-site integration capabilities July 08, 2026 07:05 ET | Source: BiomX NETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
Automobile
Tech
Entertainment
-
Dance Without Borders: BYU Ballroom Dance Gives Historic Performances in India
New Delhi | Bengaluru, India The BYU Ballroom Dance Company lit up stages in India for the first time, enchanting over 1,000 audience members with show-stopping performances held on 4 and 6 June 2026 in the nation’s capital and a grand finale in Bengaluru on 9 June. Distinguished guests, including government, interfaith, and community leaders,…
Health
-
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities
Proposed acquisition of an Israeli company with approximately 20 years of operating experience is expected to strengthen BiomX’s Detection-Analysis-Response strategy through security systems, fire detection, access control, intrusion detection, building-control, electrical infrastructure and secure-site integration capabilities July 08, 2026 07:05 ET | Source: BiomX NETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
-
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
July 07, 2026 09:12 ET | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program…
-
Medicine Beyond Borders: Zydus Hospital, Ahmedabad, Emerges as a Preferred Destination for International Patients
AHMEDABAD, India, July 7, 2026 /PRNewswire/ — Quality healthcare should never be a matter of geography or means, yet for patients in many parts of the world, it still is. As illnesses grow more complex and treatments advance, the gap between what is medically possible and what is locally accessible keeps widening for many. Patients travelling…
-
Zealand Pharma – Transactions related to share buy-back program (week 27, 2026)
Company announcement No. 31 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the…
-
World’s First International Patient Begins Treatment with Newly Approved Solid Tumor CAR-T Therapy at Jiahui International Cancer Center
SHANGHAI, July 6, 2026 /PRNewswire/ — Jiahui International Cancer Center (JICC) has welcomed the world’s first international patient to begin treatment with Satri-cel, the world’s first approved CAR-T therapy for a solid tumor, marking a historic milestone in expanding global access to China’s latest oncology innovations. Josh, a 59-year-old patient from New Zealand with advanced…
-
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
